Lipid changes after switch from tenofovir disoproxil fumarate to tenofovir alafenamide: a longitudinal cohort study

被引：0
|
作者：
Berger, F. [1 ]
Milinkovic, A. [2 ]
Arenas-Pinto, A. [3 ]
Mauss, S. [1 ]
机构：
[1] Ctr HIV & Hepatogastroenterol, HIV & Hepatogastroenterol, Dusseldorf, Germany
[2] Chelsea & Westminster Hosp, Dept HIV Med, London, England
[3] UCL, Inst Global Hlth, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P195
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
    Milinkovic, Ana
    Berger, Florian
    Arenas-Pinto, Alejandro
    Mauss, Stefan
    AIDS, 2019, 33 (15) : 2387 - 2391
  • [22] Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV
    不详
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : I21 - I21
  • [23] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Shao-Ming Chiu
    Kuo-Chin Chang
    Tsung-Hui Hu
    Chao-Hung Hung
    Jing-Houng Wang
    Sheng-Nan Lu
    Chien-Hung Chen
    Digestive Diseases and Sciences, 2023, 68 : 665 - 675
  • [24] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?
    Squillace, N.
    Ricci, E.
    Menzaghi, B.
    Migliorino, G.
    De Socio, G.
    Passerini, S.
    Martinelli, C.
    Mameli, M.
    Maggi, P.
    Falasca, K.
    Cordier, L.
    Celesia, B.
    Salomoni, E.
    Di Biagio, A.
    Pellicano, G.
    Bonfanti, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [25] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought
    Mak, Lung-Yi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (05): : 420 - 421
  • [26] Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis
    Rivera, Adovich S.
    Pak, Katherine
    Mefford, Matthew T.
    Hechter, Rulin C.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (02):
  • [27] Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide
    Schafer, Jason J.
    Zimmerman, Matty
    Walshe, Ciara
    Cerankowski, Jesse
    Shimada, Ayako
    Keith, Scott W.
    OBESITY, 2022, 30 (06) : 1197 - 1204
  • [28] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Chiu, Shao-Ming
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Chen, Chien-Hung
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 665 - 675
  • [29] The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen
    Taramasso, Lucia
    Berruti, Marco
    Briano, Federica
    Di Biagio, Antonio
    AIDS, 2020, 34 (06) : 877 - 881
  • [30] Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
    Schafer, Jason J.
    Sassa, Kaitlin N.
    O'Connor, Jaclyn R.
    Shimada, Ayako
    Keith, Scott W.
    DeSimone, Joseph A.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (10): : 1 - 4
12345